Bristol Myers wants to pull out of its Abraxane deal in China. BeiGene says no way
A year and a half after Chinese officials ordered BeiGene to stop selling Bristol Myers Squibb’s Abraxane in the wake of an alarming inspection of a US facility, the manufacturing issues at the root of the import suspension still appear unresolved.
And Bristol Myers wants to axe the Abraxane supply deal altogether.
But BeiGene, which is currently in arbitration proceedings against its Big Pharma partner, won’t let it off the hook so easily.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,100+ biopharma pros reading Endpoints daily — and it's free.